🇺🇸 FDA
Pipeline program

Reslizumab

RES-2020-20

Approved mab completed

Quick answer

Reslizumab for Asthma; Eosinophilic is a Approved program (mab) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Asthma; Eosinophilic
Phase
Approved
Modality
mab
Status
completed

Clinical trials